GET THE APP

..

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

Factors Affecting Survival in Egyptian Patients Suffering from Urinary Bladder Cancer: A Multicenter Retrospective Study

Abstract

Ahmed Aly Nagy, Hosam Darweish, Hend M. Hamdey Rashed Elkalla, Heba Abdu-allah, Lamiaa Moustafa Ahmed, Ebtehal Mohamed Salah and Rasha Haggag

Background: Bladder cancer is the second most common malignancy among Egyptian males.

Patients and methods: To investigate the factors affecting survival in Egyptian patients suffering from urinary bladder cancer, we analyzed the geographical patterns of 564 bladder cancers patients from Oncology Departments of Ain Shams University, Mansoura University, Zagazig University and Damietta oncology centerover a period of 7 years between January 2006 and September 2013.

Results: Among the included 564 patients, Males represented 72.5% of the patients. While, 27.5% were female with a male to female ratio of 2.6, 227 patients presented with non-metastatic and 337 patients with metastatic urinary bladder cancer. Grade III was found in 36% of our patients and 60% of them had stage IV. Mean DFS was (9.15 ± 0.5) and (4.4 ± 0.1) while, mean OS was (13.5 ± 0.7) and (7.5 ± 0.15) months for non-metastatic, and metastatic patients, respectively. In univariate analysis, patients with no bilharzial infection, Non-SCC, responding patients had significant better DFS and OS vs. patients with bilharzial infection, SCC, non-responding patients (respectively, p=0.001 for all). In multivariate analysis, response (OS and PFS), SCC (OS and PFS) and bilharzias is (OS and PFS) where found to be highly statistically significant (Cox regression, P<0.001 for all) in the metastatic and non-metastatic group of patients.

Conclusion: Non-responding, SCC type and bilharzial infected patients had significant independent poor prognostic factors for OS and PFS in the metastatic and non-metastatic group of patients.

PDF

Share this article

Google Scholar citation report
Citations: 3968

Cancer Science & Therapy received 3968 citations as per Google Scholar report

Cancer Science & Therapy peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward